SCHEMBL1938201

SCHEMBL1938201

C[C@@]1(n2cnc3c(N)nc(N)nc32)O[C@H](CO)[C@@H](O)[C@H]1O

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
AHCY P23526 1/20 0.46
ADORA2A P29274 4/20 0.43
CYP2C19 P33261 1/20 0.43
ADORA2B P29275 2/20 0.42
CDK1 P06493 1/20 0.42
CCNB1 P14635 1/20 0.42
CCNE1 P24864 1/20 0.42
CDK2 P24941 1/20 0.42
ADORA3 P0DMS8 2/20 0.42
ADORA1 P30542 1/20 0.42
PI4KA P42356 1/20 0.42
PI4K2B Q8TCG2 1/20 0.42
PI4K2A Q9BTU6 1/20 0.42
PI4KB Q9UBF8 1/20 0.42
LMNA P02545 1/20 0.42
NT5E P21589 1/20 0.42
HIF1A Q16665 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6685951 1.00 AHCY (0.46) AHCYADORA2ACYP2C19ADORA2BCDK1
SCHEMBL20798007 0.90 ADORA2A (0.43) ADORA2AADORA2BADORA3ADORA1PI4KA
SCHEMBL226038 0.90 ADORA2A (0.43) ADORA2AADORA2BADORA3ADORA1PI4KA
SCHEMBL6538264 0.89 ADORA2A (0.57) ADORA2ACDK1ADORA3ADORA1LMNA
SCHEMBL2458484 0.87 BLM (0.44) CYP2C19ADORA3LMNA
Phosphoric Acid SCHEMBL1300003 0.85 RNASEL (0.42) ADORA2AADORA2BADORA3ADORA1PI4KA
SCHEMBL18537398 0.85 PI4KA (0.55) AHCYADORA2AADORA2BADORA3ADORA1
SCHEMBL3794703 0.85 PI4KA (0.55) AHCYADORA2AADORA2BADORA3ADORA1
SCHEMBL18680910 0.85 PI4KA (0.55) AHCYADORA2AADORA2BADORA3ADORA1
SCHEMBL16258664 0.85 PI4KA (0.55) AHCYADORA2AADORA2BADORA3ADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020257275-A1 IMPROVED IN VITRO TRANSCRIPTION PURIFICATION PLATFORM ARCTURUS THERAPEUTICS, INC. (US) 2020-12-24 WO claimed
EP-3681513-A1 RNAI AGENTS AND COMPOSITIONS FOR INHIBITING EXPRESSION OF ANGIOPOIETIN-LIKE 3 (ANGPTL3), AND METHODS OF USE Arrowhead Pharmaceuticals, Inc. (US) 2020-07-22 EP claimed
WO-2019055633-A1 RNAI AGENTS AND COMPOSITIONS FOR INHIBITING EXPRESSION OF ANGIOPOIETIN-LIKE 3 (ANGPTL3), AND METHODS OF USE Arrowhead Pharmaceuticals, Inc. (US) 2019-03-21 WO claimed
WO-2024137993-A2 ENGINEERED GUIDE RNAS AND POLYNUCLEOTIDES SHAPE THERAPEUTICS INC. (US) 2024-06-27 WO disclosed
EP-4359078-A2 COMPOSITIONS AND METHODS FOR MODULATING EXPRESSION OF GENES Versameb AG (CH) 2024-05-01 EP disclosed
EP-4359533-A2 COMPOSITIONS AND METHODS FOR MODULATING EXPRESSION OF GENES Versameb AG (CH) 2024-05-01 EP disclosed
US-20240117354-A1 COMPOSITIONS AND METHODS FOR MODULATING EXPRESSION OF GENES VERSAMEB AG (CH) 2024-04-11 US disclosed
US-20240117361-A1 COMPOSITIONS AND METHODS FOR MODULATING EXPRESSION OF GENES VERSAMEB AG (CH) 2024-04-11 US disclosed
CN-117813380-A Compositions and methods for modulating expression of genes 维萨梅布有限公司 2024-04-02 CN disclosed
CN-116710108-A Compositions and methods for simultaneous modulation of gene expression 维萨梅布有限公司 2023-09-05 CN disclosed
US-20230183746-A1 COMPOSITIONS FOR TRANSFER OF CARGO TO CELLS Sixfold Bioscience Ltd. (GB) 2023-06-15 US disclosed
EP-2331129-A1 COMPOSITION COMPRISING A COMPLEXED (M)RNA AND A NAKED MRNA FOR PROVIDING OR ENHANCING AN IMMUNOSTIMULATORY RESPONSE IN A MAMMAL AND USES THEREOF Curevac GmbH (DE) 2011-06-15 EP disclosed
WO-2010037408-A1 COMPOSITION COMPRISING A COMPLEXED (M)RNA AND A NAKED MRNA FOR PROVIDING OR ENHANCING AN IMMUNOSTIMULATORY RESPONSE IN A MAMMAL AND USES THEREOF CUREVAC GMBH (DE) 2010-04-08 WO disclosed
WO-2010037539-A1 COMPOSITION COMPRISING A COMPLEXED (M)RNA AND A NAKED MRNA FOR PROVIDING OR ENHANCING AN IMMUNOSTIMULATORY RESPONSE IN A MAMMAL AND USES THEREOF CUREVAC GMBH (DE) 2010-04-08 WO disclosed
WO-2009046739-A1 COMPOSITION FOR TREATING PROSTATE CANCER (PCA) CUREVAC GMBH (DE) 2009-04-16 WO disclosed
WO-2009046738-A1 COMPOSITION FOR TREATING LUNG CANCER, PARTICULARLY OF NON-SMALL LUNG CANCERS (NSCLC) CUREVAC GMBH (DE) 2009-04-16 WO disclosed
EP-1525209-A2 1'-, 2'- AND 3' -MODIFIED NUCLEOSIDE DERIVATIVES FOR TREATING FLAVIVIRIDAE INFECTIONS Idenix (Cayman) Limited (KY) 2005-04-27 EP disclosed
US-20040214198-A1 Allele-targeted RNA interference UNIVERSITY OF MASSACHUSETTS 2004-10-28 US disclosed
WO-2004046324-A2 ALLELE-TARGETED RNA INTERFERENCE UNIVERSITY OF MASSACHUSETTS (US) 2004-06-03 WO disclosed
WO-2004003000-A2 1’-, 2'- AND 3'- MODIFIED NUCLEOSIDE DERIVATIVES FOR TREATING FLAVIVIRIDAE INFECTIONS IDENIX (CAYMAN) LIMITED (KY) 2004-01-08 WO disclosed